Biodexa Pharmaceuticals Plc (BDRX) Fair Value 2026

BDRX · Biotechnology ·

By CirclFi Research Team · Data from SEC EDGAR, FRED & GDELT

Quality Score

4.6 /10

32 fundamental signals · 0 models active

Value Trap Risk

LOW (27/100)

Quick Summary — As of 2026-08-28, Biodexa Pharmaceuticals Plc (BDRX) trades at $0.87. QOC: 4.6/10. Value Trap Risk: 27/100 (LOW). 0/13 models active.

Key Facts

Ticker
BDRX
Price
$0.87
Quality Score
4.6/10
Value Trap Risk
27/100
Models Active
0/13
Last Updated
Strength: 0 independent models provide multi-angle coverage
Risk: Below-average Quality Score of 4.6/10 signals weak fundamentals

What Fair Value Does Each Model Give BDRX?

0 Intrinsic Value Models vs. Current Price ($0.87)

Core Models (Unlocked)
Model Fair Value Upside

All Models Active

All 0 models are displayed above.

What Is Biodexa Pharmaceuticals Plc (BDRX) Worth in 2026?

According to the CirclFi Deep Alpha Valuation Engine, Biodexa Pharmaceuticals Plc currently lacks sufficient data across our 13-model framework. As more financial data is processed from SEC filings, our models will generate intrinsic value estimates.

What Do the Models Say About BDRX?

0 of 13 models are currently active for BDRX. See which stocks rank higher →

How Does BDRX Rank in Biotechnology?

Among 625 Biotechnology stocks, BDRX ranks #415 by Quality of Company score. CirclFi's QOC score of 4.6/10 evaluates 32 fundamental signals. A score of 4.6 reflects mixed fundamentals.

See all Most Undervalued Biotechnology Stocks →

Biodexa Pharmaceuticals Plc's positioning within the Biotechnology segment means that market exclusivity window plays an outsized role in fundamental analysis. The sector's unique characteristics — including partnership and licensing deals — shape both the opportunity set and risk profile.

Is BDRX a Value Trap?

CirclFi's Value Trap algorithm assigns BDRX a score of 27/100 (LOW). This indicates low risk. The financial profile does not exhibit typical value trap warning signs. The score cross-references apparent undervaluation against fundamental deterioration signals. Browse lowest value-trap stocks →

Multi-Model Methodology

0 of 13 models are active for Biodexa Pharmaceuticals Plc. Limited activation may indicate insufficient history. Each model applies a fundamentally different valuation philosophy. See the complete methodology →

According to the CirclFi Quality of Company (QOC) framework, Biodexa Pharmaceuticals Plc earns a quality score of 4.6/10. This mixed rating reflects the company's standing across 32 fundamental signals spanning profitability, growth consistency, balance sheet strength, and capital allocation efficiency.

CirclFi runs 13 independent models for each stock. Browse all stocks with 13-model coverage →

Data Sources & Confidence

Every BDRX valuation is built from SEC EDGAR XBRL filings — 700+ standardized financial tags. Macroeconomic context from FRED calibrates discount rates, while GDELT news sentiment feeds into our Sentiment SOTP model. All pipelines run daily. Read the complete data methodology →

CirclFi's output is a research starting point, not a buy/sell signal. All data updates daily. Read the full methodology →

This analysis is produced by the CirclFi Valuation Engine using quantitative models applied to SEC EDGAR filings, public market feeds, and FRED macroeconomic indicators. It is not financial advice.

Read the full investment analysis: Should You Buy Biodexa Pharmaceuticals Plc Stock in 2026? →

Bull case, bear case, risk factors & peer comparison — updated daily

Which Similar Biotechnology Stocks Should You Also Analyze?

11 related Biotechnology stocks with 13-model coverage

ACXPAcurx Pharmaceuticals, Inc.QOC 4.6BMEABiomea Fusion, Inc.QOC 4.6OGENOragenics, Inc.QOC 4.6NMRANeumora Therapeutics, Inc.QOC 4.6CNTXContext Therapeutics Inc.QOC 4.6AXIMAXIM Biotechnologies, Inc.QOC 4.6LNAILunai Bioworks Inc.QOC 3.5XNCRXencor, Inc.QOC 6.4TARAProtara Therapeutics, Inc.QOC 5.2EXELExelixis, Inc.QOC 9.6INCYIncyte CorporationQOC 9.5

Read investment analysis: ACXP · BMEA · OGEN · NMRA · CNTX · AXIM · LNAI · XNCR · TARA · EXEL · INCY

Which Other Stocks Have a Similar Quality Score to BDRX?

6 companies across all industries closest to BDRX’s Quality of Company score of 4.6/10.

BMEBlackRock Health Sciences TrustQOC 4.6ASTLAlgoma Steel Group Inc.QOC 4.6NAKNorthern Dynasty Minerals Ltd.QOC 4.6VLTInvesco High Income Trust IIQOC 4.6AMBPArdagh Metal Packaging S.A.QOC 4.6NVDANVIDIA CorporationQOC 10.0

Read investment analysis: BME · ASTL · NAK · VLT · AMBP · NVDA

Where Does BDRX Sit in CirclFi's Biotechnology Rankings?

BDRX is ranked against every other Biotechnology stock CirclFi covers in each of these screens.

See all Biotechnology stocks ranked →

What Else Do Investors Ask About Biodexa Pharmaceuticals Plc’s Valuation?

What is Biodexa Pharmaceuticals Plc's intrinsic value in 2026?

CirclFi does not yet have enough active models to publish a median fair value for Biodexa Pharmaceuticals Plc (BDRX). The Quality of Company score is 4.6/10 across 32 fundamental signals. All models use SEC EDGAR filings updated daily. See our methodology page for how each model works.

Is BDRX overvalued or undervalued right now?

At $0.87, 0 of 0 active models suggest BDRX may be undervalued, while 0 indicate potential overvaluation. The assessment depends on which methodology best fits Biodexa Pharmaceuticals Plc's business model in Biotechnology.

What does a Quality of Company score of 4.6 mean for BDRX?

Biodexa Pharmaceuticals Plc's QOC of 4.6/10 reflects 32 fundamental signals: profitability margins, revenue growth consistency, balance sheet leverage, free cash flow generation, and capital allocation efficiency. Scores below 5 flag potential fundamental weaknesses requiring careful analysis.

How many valuation models does CirclFi run on BDRX?

CirclFi analyzes BDRX with 13 institutional-grade models daily: Bayesian DCF (Monte Carlo + jump-diffusion), EPV (Greenwald zero-growth), EROIC Spread (McKinsey reinvestment), First Chicago (3-scenario), Markov DDM (regime-switching), ML-RIV (machine learning residual income), Dynamic NAV (asset-based), PWERM (option-theoretic), Regime Cross-Sectional (relative), Sentiment SOTP (hybrid), CUCE Ensemble (meta-model), FTNN Topology (neural network), and RCMH-DCF (conditional regime). Currently 0 of 13 are active for this stock. Read the full methodology →

Is BDRX a value trap in 2026?

Biodexa Pharmaceuticals Plc's Value Trap score is 27/100 (LOW). This low score indicates the current valuation is not artificially depressed by fundamental deterioration, suggesting genuine opportunity rather than a trap. Browse stocks by value-trap risk →

Cite this analysis — “CirclFi assigns Biodexa Pharmaceuticals Plc (BDRX) a Quality of Company score of 4.6/10 across 32 fundamental signals as of 2026-08-28.” Source: circlfi.com/stock/BDRX/ · Methodology
Primary sources for this BDRX valuation
  • Financial statements: Biodexa Pharmaceuticals Plc 10-K and 10-Q filings on SEC EDGAR (CIK 0001643918) — 700+ standardized XBRL tags, published by the U.S. Securities and Exchange Commission.
  • Discount-rate inputs: FRED, Federal Reserve Bank of St. Louis — risk-free rates, VIX, yield curve, inflation.
  • News sentiment: The GDELT Project — global media tone, input to the Sentiment SOTP model.
  • Model definitions: CirclFi methodology — the published specification for all 13 models, including the academic sources each one implements.

Market data for BDRX as of ; valuations recomputed .